Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02564744 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
A Phase 2 study, sponsored by Debiopharm International.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT02564744 is a Phase 2 study that has completed, run by Debiopharm International. The registered enrollment target is 100 participants.
The verdict
NCT02564744, a Phase 2 study, has completed, sponsored by Debiopharm International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The primary purpose of the study was to determine the safety and tolerability, anti-tumor activity of the proposed Debio 1562 dose regimens in combination with rituximab.
Interventions
- DRUG Rituximab
- DRUG Debio 1562
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-06-05 |
| Est. Completion | 2021-06-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02564744
The ClinicalTrials.gov registry entry for NCT02564744 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT02564744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02564744 about?
NCT02564744 is a clinical study titled "Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL". The primary purpose of the study was to determine the safety and tolerability, anti-tumor activity of the proposed Debio 1562 dose regimens in combination with rituximab.
What is the current status of trial NCT02564744?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2016-06-05. Estimated completion is 2021-06-25.
What interventions are being tested in trial NCT02564744?
The interventions under investigation include: Rituximab (DRUG), Debio 1562 (DRUG).
Who is sponsoring clinical trial NCT02564744?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.